Results from this trial supported the indication for margetuximab in combination with chemotherapy for the treatment of adult patients with HER2+ MBC who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease (21). Here, ERBB2 is linked to metastatic neoplasm.